Somatropin biosimilar - Biopartners/LG Chem
Alternative Names: Declage; Eutrophine; Eutropin; Eutropin Plus; LB-03002; rhGH; Somatropin Biopartners; Somatropina Biopartners; SR-rhGH; ValtropinLatest Information Update: 13 Jan 2022
At a glance
- Originator LG Life Sciences
- Developer Biopartners GmbH; LG Chem; LG Life Sciences; Merck KGaA
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Short stature; Somatotropin deficiency
- Phase III Prader-Willi syndrome
Most Recent Events
- 02 Jan 2020 LG Chem completes a phase I trial in Volunteers in South Korea (SC) (NCT04085224)
- 16 Sep 2019 LG Chem plans a bioavailability phase I trial in Healthy volunteers (NCT04085224) (SC)
- 03 Aug 2017 Phase-II development for Short stature (In children, Treatment-naive) is ongoing in South Korea (SC, Controlled release)